MétaCan
Menu
Back to cohort
Record W4412487071 · doi:10.1093/ced/llaf302

Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis

2025· article· en· W4412487071 on OpenAlexaff
Gianluca Avallone, Andrea Bombelli, Luca Valtellini, Gianluca Tavoletti, Benedetta Gallì, Mariateresa Rossi, Martina Maurelli, Giampiero Girolomoni, Luigi Gargiulo, Alessandra Narcisi, Francesca di Vico, Maddalena Napolitano, Laura Lazzeri, Laura Calabrese, Stefano Caccavale, Anna Balato, Francesca Barei, Paolo Calzari, Caterina Foti, Ilaria Trave, Emanuele Cozzani, Franco Rongioletti, Sveva Lenti, Carlotta Gurioli, Eustachio Nettis, Francesca Caroppo, Enzo Errichetti, Laura Bonzano, Niccolò Gori, Ketty Peris, Serena Lembo, Laura Del Regno, Maria Esposito, Maria Concetta Fargnoli, Paola Savoia, Elia Esposto, Roberta Giuffrida, Fabrizio Guarneri, Cataldo Patruno, Elena Pezzolo, Luca Stingeni, Katharina Hansel, Luca Mastorino, Michela Ortoncelli, Simone Ribero, Angelo Valerio Marzano, Silvia Mariel Ferrucci

Bibliographic record

VenueClinical and Experimental Dermatology · 2025
Typearticle
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsChildren's & Women's Health Centre of British Columbia
Fundersnot available
KeywordsPrurigo nodularisMedicineDermatologyPrurigoDermatologic agentsBiologyGenetics

Abstract

fetched live from OpenAlex

BACKGROUND: Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, Janus kinase inhibitors (JAKis) may be considered, although real-world evidence remains limited. OBJECTIVES: To investigate clinical findings and treatment outcomes among patients diagnosed with PN and treated with JAKis in a real-world setting. METHODS: Retrospective cohort study across 23 Italian tertiary referral hospitals. Patients with PN were eligible if aged ≥ 18 years and had received a JAKi with a minimum follow-up of 12 weeks. The primary outcome was defined as the proportion of patients achieving a reduction of ≥ 4 points from baseline in the Peak Pruritus Numerical Rating Scale score. Key secondary outcomes included the rates of patients reaching a significant reduction in Investigator Global Assessment of Prurigo Nodularis Stage (IGA PN-S) and Investigator Global Assessment of Prurigo Nodularis Activity (IGA PN-A) scores. RESULTS: Of the total, 71 patients met the inclusion criteria. At week 16, the proportion of patients achieving the primary outcome was 94% for upadacitinib [n = 52/55; 95% confidence interval (CI) 87-100%], 83% for abrocitinib (n = 10/12; 95% CI 52-98%) and 100% for baricitinib (n = 4/4; 95% CI 40-100%), with results sustained at week 24. An IGA PN-A score of 0/1 was achieved in 90% of patients treated with upadacitinib and abrocitinib and in 50% of those on baricitinib by week 24. Improvements were observed across all other secondary outcomes assessed, with no safety concerns reported. CONCLUSIONS: This study suggests that JAKis can achieve clinically meaningful outcomes in PN irrespective of atopic background, supporting their use across diverse patient profiles. Further research is warranted to validate these observations and explore their long-term effects.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.025
Threshold uncertainty score0.608

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.408
Teacher spread0.381 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical and Experimental DermatologySame topicDermatology and Skin DiseasesFrench-language works237,207